The WinSanTor Solution


Unmet Need

Neuropathy affects nearly 1 in 15 Americans. It is one of the largest unmet medical challenges existing today, with no FDA-approved treatments outside analgesics.

Peripheral Neuropathies


We are working to treat peripheral neuropathy by reversing and regenerating nerves. Our results validate the discovery of a pathway to augment nerve growth and sensory function.

Our Solution


Who We Are:
+ Key Opinion Leaders
+ Leading Institutional Stakeholders
+ Proven Management Team
+ World Class Advisors

The Team


We are focused on managing global resources to accelerate the development of treatment for patients with peripheral neuropathy.


Meet June

June is an 85-year-old woman who got neuropathy from the radiation treatment for her breast cancer. She has lost feeling in her feet and experiences numbing in her calves. Like so many others, she now has to use a walker.

Read More Patient Testimonials

Recent News

5 days ago
Interested in chatting with us? Join us on 10/13 at 1 pm EST for a live Zoom discussion with our CEO, Stan Kim, and the Peripheral Neuropathy Success Stories Facebook group. To sign up, join the private group here:
5 days ago
We know that peripheral neuropathy is much more than just tingling and burning sensations; it can affect your mental health and quality of life. Take care of yourself and loved ones today and every day: #WorldMentalHealthDay
2 weeks ago
Do you know an older peripheral neuropathy patient who lives on their own? Here are some ways to keep them safe at home: #OlderPersonsDay


WinSanTor Inc. is a private biotechnology company focused on the discovery and development of treatments for peripheral neuropathies. WinSanTor recently completed Phase 1 trials for its lead drug, WST-057, and will begin recruiting for its Phase 2 trials in Canada to treat patients with diabetic peripheral neuropathy.

Investor Information

Conquering Diabetic Neuropathy

Drs. Calcutt and Fernyhough on WST-057 and on treating and preventing nerve damage caused by diabetes.